AbbVie, which in September reported that tavapadon had met the primary and secondary endpoints in a Phase 3 fixed-dose monotherapy trial, said it is on track to file for Food & Drug Administration ...

Global progress toward nutrition targets is slow, with few countries on track to meet goals for anemia, stunting, and child ...

AbbVie on Monday said a third late-stage study of its tavapadon drug candidate hit its key goals in the neurodegenerative disorder Parkinson's disease. AbbVie said tavapadon met the primary ...